Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

Health Canada Clears Palisade Bio ASCENTRA-UC Trial

Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026

Sentiment
5
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The Canada — Health Canada clearance is a modest positive milestone for Palisade Bio, expanding the ASCENTRA-UC trial into Canada and supporting enrollment timelines, but it does not change near-term revenue prospects given efficacy data is not expected until the second half of 2027. Market reaction was muted, with PALI shares trading down 2.96% at $1.64, reflecting limited immediate financial impact for a clinical-stage biopharmaceutical company.

biopharmaceutical healthcare

Palisade Bio, Inc. (Nasdaq: PALI) announced that Canada — Health Canada has cleared its Clinical Trial Application (CTA) for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. The clearance enables Palisade to advance clinical trial activities in Canada, expanding the study's geographic reach and supporting planned enrollment, and follows prior regulatory clearance in the United States. ASCENTRA-UC is a global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase 2 trial expected to enroll approximately 204 patients, evaluating once-daily 15 mg and 30 mg doses of PALI-2108 against placebo. The primary endpoint is clinical remission at Week 12 measured by the modified Mayo Score, with key secondary endpoints including clinical response, endoscopic improvement and histologic-endoscopic mucosal improvement. The study also includes a 36-week maintenance phase extension to assess durability of response and longer-term safety through Week 48. Palisade Bio stated it remains on track to begin patient dosing in the second half of 2026, with primary efficacy results from the 12-week induction period expected in the second half of 2027. PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon. Palisade shares traded between $0.64 and $2.86 over the last year, and PALI was trading down 2.96% at $1.64 following the announcement.

90 Canada — Health Canada cleared clinical trial application Palisade Bio
stock
Palisade Bio is the central entity of this event, receiving Canada — Health Canada clearance for its ASCENTRA-UC Phase 2 trial of PALI-2108, which expands the study into Canada and supports planned enrollment. The clearance is a positive execution milestone but shares traded down 2.96% at $1.64, indicating limited near-term market impact.
Importance 100.0 Sentiment 10.0
govactor
Canada — Health Canada cleared Palisade Bio's Clinical Trial Application for ASCENTRA-UC, enabling clinical trial activities in Canada and expanding the study's geographic reach.
Importance 80.0 Sentiment 0.0
cnt
Canada becomes an additional trial location for the ASCENTRA-UC study following Canada — Health Canada clearance, supporting site activation and patient enrollment.
Importance 30.0 Sentiment 0.0
cnt
The United States previously granted regulatory clearance for the ASCENTRA-UC trial, which together with the Canadian clearance advances Palisade Bio's global site activation and enrollment strategy.
Importance 20.0 Sentiment 0.0
Canada trade rivals ↔ United States Canada views the United States as a strained partner and trade rival, facing significant tariffs and renegotiation of tr
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.